Komori
Pharmarise Holdings (2796) · InitiativeDropped

Capital and Business Alliance With Asparant Group and AG2 Fund

First written in FY2019-Q2. 2 of 4 entries say "Restated". Latest entry: FY2025.

4entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019-Q2 – FY20252019: 120192020: 120202021: 020212022: 020222023: 020232024: 120242025: 12025
Same theme, other companies
Capital and Business Alliance with Aspirant Group and AG2 Fund, and Its TerminationA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025DroppedAnnual report

    「The company entered into a capital and business alliance with SUZUKEN CO.,LTD. and terminated its business and capital alliance with Aspirant Group Co., Ltd. and AG2 Investment Limited Partnership, which Aspirant Group operates and manages.」

    The capital and business alliance with Aspirant Group and AG2 Fund was terminated.
  2. FY2024-Q3RestatedAnnual report

    「As part of these initiatives, in November 2023 the company entered into a capital and business alliance with SUZUKEN CO.,LTD. and began working to create new added value and jointly address social issues by combining and integrating the respective management resources and expertise of both parties, including their respective strengths and functions.」

    The company has continued its existing capital and business alliance policy and begun initiatives to utilize the respective management resources and expertise of SUZUKEN CO.,LTD. and create added value through the alliance.
  3. FY2020RestatedAnnual report

    「The appointment of the individual was based on the capital and business alliance agreement announced on 8 November 2018 between the company, Aspirant Group Co., Ltd. and AG2 Investment Limited Partnership, which Aspirant Group operates and manages, under which 2 individuals from Aspirant Group would participate in the company's management as directors.」

    The framework for accepting 2 outside directors from the capital and business alliance partner continues to serve as the basis for director appointments.
  4. FY2019-Q2First statedAnnual report

    「The company entered into a capital and business alliance agreement with AG, which has extensive expertise and a strong track record in improving business methods and the earnings structure, areas that the Group regarded as management challenges.」

    On 8 November 2018, the company entered into a capital and business alliance agreement with Aspirant Group Co., Ltd. and AG2 Investment Limited Partnership, which it operates and manages. The company introduced a framework under which it would receive operational support to improve its existing businesses, strengthen and improve the efficiency of M&A and new store openings, and enhance its management control structure.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Pharmarise Holdings's next results are scheduled for 2026-09-17. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Capital and Business Alliance With Asparant Group and AG2 Fund | Pharmarise Holdings Corporation (2796) | Komori